SG11202112710VA - Il-2 mutant protein proliferating immune cells - Google Patents

Il-2 mutant protein proliferating immune cells

Info

Publication number
SG11202112710VA
SG11202112710VA SG11202112710VA SG11202112710VA SG11202112710VA SG 11202112710V A SG11202112710V A SG 11202112710VA SG 11202112710V A SG11202112710V A SG 11202112710VA SG 11202112710V A SG11202112710V A SG 11202112710VA SG 11202112710V A SG11202112710V A SG 11202112710VA
Authority
SG
Singapore
Prior art keywords
immune cells
mutant protein
proliferating immune
protein proliferating
mutant
Prior art date
Application number
SG11202112710VA
Inventor
Hui Hu
Ying Zhang
Original Assignee
Shanghai Gp Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Gp Biotech Co Ltd filed Critical Shanghai Gp Biotech Co Ltd
Publication of SG11202112710VA publication Critical patent/SG11202112710VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
SG11202112710VA 2019-05-14 2020-05-14 Il-2 mutant protein proliferating immune cells SG11202112710VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910399641.1A CN111944036A (en) 2019-05-14 2019-05-14 Mutant protein for proliferating immune cells
PCT/CN2020/090365 WO2020228791A1 (en) 2019-05-14 2020-05-14 Il-2 mutant protein proliferating immune cells

Publications (1)

Publication Number Publication Date
SG11202112710VA true SG11202112710VA (en) 2021-12-30

Family

ID=73289362

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112710VA SG11202112710VA (en) 2019-05-14 2020-05-14 Il-2 mutant protein proliferating immune cells

Country Status (10)

Country Link
US (1) US20220227829A1 (en)
EP (1) EP3971205A4 (en)
JP (1) JP2022533636A (en)
KR (1) KR20220008323A (en)
CN (2) CN111944036A (en)
AU (1) AU2020274833A1 (en)
BR (1) BR112021022621A2 (en)
CA (1) CA3139833A1 (en)
SG (1) SG11202112710VA (en)
WO (1) WO2020228791A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515247A (en) 2020-03-31 2023-04-12 ハンミ ファーマシューティカル カンパニー リミテッド Novel immunologically active interleukin-2 analogues
CN113667003A (en) * 2020-05-14 2021-11-19 上海盖浦生物科技有限公司 Mutant protein for proliferating regulatory T cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
AU2002355955A1 (en) * 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
ES2381025T3 (en) * 2001-12-04 2012-05-22 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
BRPI0507026A (en) * 2004-02-09 2007-04-17 Human Genome Sciences Inc albumin fusion proteins
CN1930300A (en) * 2004-03-05 2007-03-14 希龙公司 In vitro test system for predicting patient tolerability of therapeutic agents
AU2011218682B2 (en) * 2005-05-11 2013-11-21 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
SI2066796T1 (en) 2006-09-20 2012-01-31 Mt Biomethan Gmbh Method and device for separating methane and carbon dioxide from biogas
EP2209487A4 (en) * 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
PE20140303A1 (en) * 2011-02-10 2014-03-22 Roche Glycart Ag MUTANT INTERLEUQUIN-2 POLYPEPTIDES
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
JP2016519651A (en) * 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． Modified toxin
CN104231068A (en) * 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 Human interleukin II mutant and application thereof
MX370283B (en) * 2014-02-06 2019-12-09 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof.
MA40721A (en) 2014-08-06 2017-06-13 The Univ Of Miami INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
CN116472281A (en) * 2020-04-28 2023-07-21 安维塔生物科学股份有限公司 Interleukin-2 polypeptide and fusion protein thereof, and pharmaceutical composition and therapeutic application thereof

Also Published As

Publication number Publication date
US20220227829A1 (en) 2022-07-21
EP3971205A4 (en) 2023-09-06
BR112021022621A2 (en) 2022-07-19
WO2020228791A1 (en) 2020-11-19
CN113939528A (en) 2022-01-14
EP3971205A1 (en) 2022-03-23
KR20220008323A (en) 2022-01-20
CA3139833A1 (en) 2020-11-19
CN111944036A (en) 2020-11-17
AU2020274833A1 (en) 2022-01-06
JP2022533636A (en) 2022-07-25

Similar Documents

Publication Publication Date Title
EP3775229A4 (en) Modified immune cells having enhanced function and methods for screening for same
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
EP3964238A4 (en) Bcma-targeting engineered immune cell and use thereof
EP3805381A4 (en) Phytase mutant
SG11202112710VA (en) Il-2 mutant protein proliferating immune cells
EP3955958A4 (en) Ebv-specific immune cells
SG11202010543QA (en) Yeast proteins
IL299911A (en) Improving immune cell function
IL287440A (en) Antigen specific cd19-targeted car-t cells
EP3791181A4 (en) Immune age and use thereof
EP3992279A4 (en) Cytokine-based immune cells and immunotherapeutic use thereof
EP4036222A4 (en) Modified immune cell and use thereof
EP4030969A4 (en) Infant chairs
IL290109A (en) Cells for improved immunotherapy and uses thereof
GB2586918B (en) Protein Powder
CA196370S (en) Rocking chair
EP3931216A4 (en) Engineered immune cells
EP3813855A4 (en) Activation of immune cells
EP3943932A4 (en) Method for providing immune cells
IL304559A (en) Self-polarizing immune cells
TWI840766B (en) Improving immune cell function
EP3906047A4 (en) Modified immune cells expressing flagellin polypeptide
IL285881A (en) Cells, compositions and methods for enhancing immune function
GB201914611D0 (en) Engineered immune cell
CA189980S (en) Armchair